Development · 21 Aug 2026
2 publishers have reported this development. Each act of reporting is below, cited.
Strides Pharma's Bengaluru manufacturing facility received an Establishment Inspection Report from the US FDA on August 20, 2026, following a cGMP inspection conducted from May 12-20, 2026.
The USFDA issued an Establishment Inspection Report (EIR) for Strides Pharma Science's Bengaluru facility following a cGMP inspection conducted from May 12 to May 20, 2026, which concluded with five observations.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.